STC1

Across TCGA pan-cancer cohorts, STC1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated STC1 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher STC1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated STC1 expression acts as an unfavorable survival marker.

CCRCC, LUAD, and GBM are the cancer types where STC1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.609	0.916	<.001	50	view →
LUAD	OS	Median	All	0.723	0.918	.003	35	view →
GBM	OS	Tertile	All	0.760	0.975	.010	18	view →
PDAC	DFS	Median	II,III,IV	0.305	0.549	.009	8	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

STC1–CCRCC (DFS)

Open the CCRCC breakdown →